Top

Allergy, Asthma & Clinical Immunology

Published in:

Open Access 01-12-2011 | Case report

Long-term benefits of omalizumab in a patient with severe non-allergic asthma

Authors: Francesco Menzella, Roberto Piro, Nicola Facciolongo, Claudia Castagnetti, Anna Simonazzi, Luigi Zucchi

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2011

Abstract

Introduction

Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.

Case presentation

We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.

Conclusion

Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.

National Heart, and Blood Institute: Morbidity and mortality: 2002. 2002, Bethesda (MD) National Heart, Lung, and Blood Institute

European Lung White Book: The first comprehensive survey on respiratory health in Europe. European Respiratory Society. Edited by: Loddenkemper R, Gibson GJ, Sybille Y. 2003, Sheffield: ERSJ, 16-25.

Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005, 60 (3): 309-16. 10.1111/j.1398-9995.2004.00772.x.CrossRefPubMed

Rodrigo GJ, Neffen H, Castro-Rodriguez JA: Efficacy and safety of subcutaneous omalizumab versus placebo ad add on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011, 139 (1): 28-35. 10.1378/chest.10-1194.CrossRefPubMed

Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH: Anti-IgE for chronic asthma in adults and children. Cochrane Database of Systematic Reviews. 2006, CD003559-2

European Medicine Agency (EMA)- Xolair. [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000606/human_med_001162.jsp&murl=menus/medicines/medicines.jsp&jsenabled=true]

GINA Global Strategy for Asthma Management and Prevention, 2006 NHI Publications No 02-3659. GINA update. 2009, [http://www.ginasthma.org]

Juniper EF, Guyatt GH, Ferrie PJ, Ferrie PJ, Griffith LE, Townsend M: Measuring quality of life in asthma. Am Rev Respir Dis. 1993, 147: 832-8.CrossRefPubMed

Lloyd Andrew, Turk Florian, Leighton Trevor, Canonica GW: Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. Journal of Medical Economics. 2007, 10 (3): 285-296. 10.3111/13696990701478856.CrossRef

10.

Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I: "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med. 2009, 103 (11): 1633-42. 10.1016/j.rmed.2009.06.014.CrossRefPubMed

11.

Van den Berge M, Pauw RG, de Monchy JGR, van Minnen CA, Postma DS, Kerstjens HA: Beneficial effects of treatment with anti-IgE antibodies (omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest. 2011, 139: 190-193. 10.1378/chest.10-0128.CrossRefPubMed

12.

Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, Menz G, Kay AB, Corrigan CJ: Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and non atopic subjects with asthma. J Allergy Clin Immunol. 1997, 99 (5): 657-665. 10.1016/S0091-6749(97)70028-9.CrossRefPubMed

13.

Beeh KM, Ksoll M, Buhl R: Elevation of total serum immunoglobulin E is associated with asthma in non allergic individuals. Eur Respir J. 2000, 16 (4): 609-614. 10.1034/j.1399-3003.2000.16d07.x.CrossRefPubMed

14.

Holgate ST, Djukanovic R, Casale T, Bousquet J: Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005, 35: 408-416. 10.1111/j.1365-2222.2005.02191.x.CrossRefPubMed

15.

MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997, 158: 1438-45.PubMed

16.

Berger P, Scotto-Gomez E, Molimard M, Marthan R, Le Gros V, Tunon-de-Lara JM: Omalizumab decreases non-specific airway hyperresponsiveness. Allergy. 2007, 62: 154-161.CrossRefPubMed

17.

Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ: A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2006, 63: 548-61.PubMedCentralCrossRefPubMed

18.

Hamilton RG, Marcotte GV, Saini SS: Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods. 2005, 303: 81-91. 10.1016/j.jim.2005.06.008.CrossRefPubMed

Title: Long-term benefits of omalizumab in a patient with severe non-allergic asthma
Authors: Francesco Menzella
Roberto Piro
Nicola Facciolongo
Claudia Castagnetti
Anna Simonazzi
Luigi Zucchi
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Allergy, Asthma & Clinical Immunology / Issue 1/2011
Electronic ISSN: 1710-1492
DOI: https://doi.org/10.1186/1710-1492-7-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-term benefits of omalizumab in a patient with severe non-allergic asthma

Abstract

Introduction

Case presentation

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2011

A case of IgG4-related tubulointerstitial nephritis concurrent with Henoch-Schönlein purpura nephritis

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma

Prevalence of asthma symptoms based on the European Community Respiratory Health Survey questionnaire and FE NO in university students: gender differences in symptoms and FE NO

Canadian clinical practice guidelines for acute and chronic rhinosinusitis

A challenging diagnosis of alpha-1-antitrypsin deficiency: identification of a patient with a novel F/Null phenotype

Allergen-specific T cell quantity in blood is higher in allergic compared to nonallergic individuals